US study documents a 27% increase in visits to emergency departments for a primary diagnosis of acute gout from 2006 to 2014.
From 2006 to 2014 in Ireland, the prevalence of hyperuricemia increased from 19.7% to 25.0% among men and from 20.5% to 24.1% among women.
All-cause and cardiovascular mortality risks were 22% and 34% higher among febuxostat-treated patients vs allopurinol recipients.
In a study, CKD patients with high trajectories of serum uric acid had nearly triple the risk for ESRD and 4.5 times the risk for death.
Among CKD patients with an eGFR of 45 mL/min/1.73 m2 or above, each 1 SD increase in baseline uric acid levels is independently associated with a 40% increased risk of kidney failure.
Febuxostat may increase the risk for heart-related death.
Uric acid-lowering therapy might improve kidney outcomes, including kidney failure events, proteinuria, and the rate of change in eGFR, and seem to reduce the risk of cardiovascular events in adults with CKD.
Each 1 standard deviation in baseline uric acid levels was associated with a significant 80% increased odds of rapid kidney function decline.
In a study of African Americans with hypertension-related CKD, metoprolol, but neither ramipril nor amlodipine, increased serum uric acid levels.
The risk for developing erectile dysfunction is 15% higher among men with than without gout.
All-cause hospitalizations in the US increased 410% from 1993 to 2014 among gout sufferers compared with 4.8% in the general population.
A DASH-style diet is associated with a reduced risk of gout, whereas a Western diet is associated with a higher risk.
Gout is uncontrolled in the majority of individuals with the condition, data show.
The multivariable-adjusted relative risk of hip fracture was 1.38 in women with history of gout.
Blacks had significantly higher median baseline serum urate levels compared to whites.
The allopurinol group had a significant 0.10 mg/dL lower final creatinine level than controls.
The DASH diet lowered serum uric acid, and this effect was greater among participants with hyperuricemia.
Odds of acute kidney injury increases by 29% with each 1 mg/dL increment in uric acid level at ICU admission.
Benefit of adding the uricosuric drug to a xanthine oxidase inhibitor persists for up to 2 years, extension study shows.
The guidelines recommend treatment strategies and state that evidence is insufficient to support therapy to lower uric acid to target levels.
Zurampic, a URAT1 inhibitor, can be combinated with a xanthine oxidase inhibitor to treat hyperuricemia tied to gout.
Serum uric acid levels of 10 mg/dL or higher are associated with an increased risk for nephrolithiasis.
Using the drug together with allopurinol helps more patients achieve target uric acid levels of less than 6 mg/dL.
In a study, CKD was 16% less likely to develop in low adherers to a DASH dietary pattern.
The effect of gout on type 2 diabetes risk was more profound in women than men.
Highest vs lowest uric acid levels associated with a 2-fold increased risk of VTE.
Odds of non-fatal stroke are 49% higher in patients in the fourth quartile of uric acid level versus those in the second quartile.
Patients with inadequately controlled gout experience lower quality of life and report worse functioning.
Unlike in adults, there is no association between uric acid, cardiorenal parameters.
Patients treated with the uric acid-lowering drug were less likely to experience a greater than 10% decline in eGFR than placebo recipients.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)